8102
-
Therapeutics and Clinical Risk Management
Open access peer-reviewed scientific and medical journals.
Dove Medical Press is now a member of the Open Access Initiative
A guide to help authors get their paper published.
Support Open Access and Dove Press
Promotional Article Monitoring - further details
Real benefits for authors, including fast-track processing of papers.
Therapeutics and Clinical Risk Management
(2,215,709) Views
Editor in Chief Professor Garry Walsh
1178-203X
Original ResearchIn-hospital resuscitation: opioids and other factors influencing survival
Karamarie Fecho, Freeman Jackson, Frances Smith, et al
Therapeutics and Clinical Risk Management 2009, 5:961-968
08 December 2009
Review
Monitored anesthesia care (MAC) sedation: clinical utility of fospropofol
Eric A Harris, David A Lubarsky, Keith A Candiotti
Therapeutics and Clinical Risk Management 2009, 5:949-959
08 December 2009
Review
Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient onsiderations and the role of lisdexamfetamine
Brian J Cowles
Therapeutics and Clinical Risk Management 2009, 5:943-948
07 December 2009
Review
An evidence-based review of natalizumab therapy in the management of Crohn’s disease
Raja GR Edula, Michael F Picco
Therapeutics and Clinical Risk Management 2009, 5:935-942
19 November 2009
Review
Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist
James P Kemp
Therapeutics and Clinical Risk Management 2009, 5:923-934
19 November 2009
Review
The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab
Richard Kelly, Stephen Richards, Peter Hillmen, et al
Therapeutics and Clinical Risk Management 2009, 5:911-921
18 November 2009
Review
Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability
Andre R Brunoni, Renerio Fraguas Jr, Felipe Fregni
Therapeutics and Clinical Risk Management 2009, 5:897-910
17 November 2009
Review
Celecoxib in arthritis: relative risk management profile and implications for patients
Gayle McKellar, Gurkirpal Singh
Therapeutics and Clinical Risk Management 2009, 5:889-896
09 November 2009
Review
New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat
James E Wraith, Jackie Imrie
Therapeutics and Clinical Risk Management 2009, 5:877-887
03 November 2009
Review
Fesoterodine for the treatment of urinary incontinence and overactive bladder
Pamela Ellsworth
Therapeutics and Clinical Risk Management 2009, 5:869-876
03 November 2009
Review
Update on the use of deferasirox in the management of iron overload
Ali Taher, Maria Domenica Cappellini
Therapeutics and Clinical Risk Management 2009, 5:857-868
30 October 2009
Review
Pediatric psoriasis: an update
Nanette B Silverberg
Therapeutics and Clinical Risk Management 2009, 5:849-856
21 October 2009
Review
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea
Hoonmo L Koo, Herbert L DuPont, David B Huang
Therapeutics and Clinical Risk Management 2009, 5:841-848
21 October 2009
Review
Antimicrobial prophylaxis in colorectal surgery: focus on ertapenem
Fausto de Lalla
Therapeutics and Clinical Risk Management 2009, 5:829-839
14 October 2009
Review
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
E Michael Lewiecki
Therapeutics and Clinical Risk Management 2009, 5:817-827
14 October 2009
Review
Artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria
Stephan Ehrhardt, Christian G Meyer
Therapeutics and Clinical Risk Management 2009, 5:805-815
06 October 2009
Mini-review
The role of urate and xanthine oxidase in vascular oxidative stress: future directions
Jacob George, Allan Struthers
Therapeutics and Clinical Risk Management 2009, 5:799-803
05 October 2009
Review
Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
Melissa K Osborn
Therapeutics and Clinical Risk Management 2009, 5:789-798
01 October 2009
Review
Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
Serena Ricciardi, Silverio Tomao, Filippo de Marinis
Therapeutics and Clinical Risk Management 2009, 5:781-787
25 September 2009
Original Research
Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures
Jun Iwamoto, Atsushi Miyata, Yoshihiro Sato, et al
Therapeutics and Clinical Risk Management 2009, 5:773-779
25 September 2009
Review
Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease
Michael Beck
Therapeutics and Clinical Risk Management 2009, 5:767-772
21 September 2009
Review
Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety
Christoph Kellinghaus
Therapeutics and Clinical Risk Management 2009, 5:757-766
21 September 2009
Review
Role of hydroxycarbamide in prevention of complications in patients with sickle cell disease
NM Wiles, J Howard
Therapeutics and Clinical Risk Management 2009, 5:745-755
21 September 2009
Original Research
Dyslipidemia in Iranian overweight and obese children
Robabeh Ghergerehchi
Therapeutics and Clinical Risk Management 2009, 5:739-743
18 September 2009
Review
Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review
Alain Monnier
Therapeutics and Clinical Risk Management 2009, 5:725-738
11 September 2009
Case report
Anticholinergic syndrome following an unintentional overdose of scopolamine
Carmela E Corallo, Ann Whitfield, Adeline Wu
Therapeutics and Clinical Risk Management 2009, 5:719-723
13 September 2009
Review
Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review
S Deandrea, O Corli, I Moschetti, et al
Therapeutics and Clinical Risk Management 2009, 5:707-718
04 September 2009
Review
Role of everolimus in the treatment of renal cell carcinoma
Saby George, Ronald M Bukowski
Therapeutics and Clinical Risk Management 2009, 5:699-706
28 August 2009
Review
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
Joan Khoo, Christopher K Rayner, Karen L Jones, et al
Therapeutics and Clinical Risk Management 2009, 5:683-698
20 August 2009
Original Research
Comparison of linear–stochastic and nonlinear–deterministic algorithms in the analysis of 15-minute clinical ECGs to predict risk of arrhythmic death
James E Skinner, Michael Meyer, Brian A Nester, et al
Therapeutics and Clinical Risk Management 2009, 5:671-682
18 August 2009
Review
Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update
Sergio Carmona, Osvaldo Bruera
Therapeutics and Clinical Risk Management 2009, 5:661-669
16 August 2009
Review
Managing pediatric hepatitis C: current and emerging treatment options
Wikrom Karnsakul, Mary Kay Alford, Kathleen B Schwarz
Therapeutics and Clinical Risk Management 2009, 5:651-660
13 August 2009
Review
Pegylated liposomal doxorubicin in ovarian cancer
Robert Strother, Daniela Matei
Therapeutics and Clinical Risk Management 2009, 5:639-650
10 August 2009
Case report
Epileptic seizure after treatment with thiocolchicoside
Pedro Giavina-Bianchi, Mara Giavina-Bianchi, Luciana Kase Tanno, et al
Therapeutics and Clinical Risk Management 2009, 5:635-637
06 August 2009
Review
Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review
W Frank Peacock IV, Jorge E Angeles, Karina M Soto, et al
Therapeutics and Clinical Risk Management 2009, 5:627-634
04 August 2009
Review
Current trends in the treatment of hepatic encephalopathy
Mohamad Rasm Al Sibae, Brendan M McGuire
Therapeutics and Clinical Risk Management 2009, 5:617-626
31 July 2009
Review
Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
Michael Neely, Andrea Kovacs
Therapeutics and Clinical Risk Management 2009, 5:595-615
31 July 2009
Review
Natalizumab in the treatment of multiple sclerosis
Brandon A Brown
Therapeutics and Clinical Risk Management 2009, 5:585-594
31 July 2009
Review
Management strategies for pulmonary sarcoidosis
Robina Kate Coker
Therapeutics and Clinical Risk Management 2009, 5:575-584
23 July 2009
Review
The levonorgestrel-releasing intrauterine system: Safety, efficacy, and patient acceptability
Megan N Beatty, Paul D Blumenthal
Therapeutics and Clinical Risk Management 2009, 5:561-574
22 July 2009
Review
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Danilo Fintini, Claudia Brufani, Marco Cappa
Therapeutics and Clinical Risk Management 2009, 5:553-559
16 July 2009
Original Research
A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers
Seyed Ali Sadjadi, James I McMillan, Navin Jaipaul, Patricia Blakely, et al.
Therapeutics and Clinical Risk Management 2009, 5:547-552
10 July 2009
Review
Finasteride in the treatment of patients with benign prostatic hyperplasia: a review
Angela B Smith, Culley C Carson
Therapeutics and Clinical Risk Management 2009, 5:535-545
08 July 2009
Review
Safety and efficacy of intrathecal ziconotide in the management of severe chronic pain
Howard S Smith, Timothy R Deer
Therapeutics and Clinical Risk Management 2009, 5:521-534
06 July 2009
Review
Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis
Devi Mukkai Krishnamurty, Atoosa Rabiee, Sanjay B Jagannath, Dana K Andersen
Therapeutics and Clinical Risk Management 2009, 5:507-520
02 July 2009
Original Research
Effects of short-term combined treatment with alendronate and elcatonin on bone mineral density and bone turnover in postmenopausal women with osteoporosis
Jun Iwamoto, Mitsuyoshi Uzawa, Yoshihiro Sato, Tsuyoshi Takeda, et al.
Therapeutics and Clinical Risk Management 2009, 5:499-505
01 July 2009
Original Research
Does nonadherence to local recommendations for empirical antibiotic therapy on admission to the intensive care unit have an impact on in-hospital mortality?
Jean-Luc Baudel, Jacques Tankovic, Fabrice Carrat, Cécile Vigneau, et al.
Therapeutics and Clinical Risk Management 2009, 5:491-498
09 July 2009
Review
Guidelines for the treatment of bacterial vaginosis: focus on tinidazole
Laura J Dickey, Michael D Nailor, Jack D Sobel
Therapeutics and Clinical Risk Management 2009, 5:485-489
23 June 2009
Review
Pharmacotherapy of pediatric and adolescent HIV infection
Susan J Schuval
Therapeutics and Clinical Risk Management 2009, 5:469-484
18 June 2009
Original Research
EUS-guided transmural drainage for peripancreatic fluid collections using fine needle and stiff fine guidewire without electrocautery: An optional safe technique
Hiroyuki Miyatani, Yukio Yoshida
Therapeutics and Clinical Risk Management 2009, 5:465-468
25 June 2009
Mini-review
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Eduardo Pimenta, Suzanne Oparil
Therapeutics and Clinical Risk Management 2009, 5:459-464
17 June 2009
Review
Substitution of anticonvulsant drugs
Bernhard J Steinhoff, Uwe Runge, Otto W Witte, Hermann Stefan, et al.
Therapeutics and Clinical Risk Management 2009, 5:449-457
22 June 2009
Review
The benefits and risks of testosterone replacement therapy: a review
Nazem Bassil, Saad Alkaade, John E Morley
Therapeutics and Clinical Risk Management 2009, 5:427-448
11 June 2009
Review
Treatment of recurrent epithelial ovarian cancer
Carmela Pisano, Giovanni S Bruni, Gaetano Facchini, Claudia Marchetti, et al.
Therapeutics and Clinical Risk Management 2009, 5:421-426
15 June 2009
Review
Role of rasagiline in treating Parkinson’s disease: effect on disease progression
Irene A Malaty, Hubert H Fernandez
Therapeutics and Clinical Risk Management 2009, 5:413-419
25 May 2009
Case report
Minimizing cardiac surgery risks in a Hepatitis C patient: Changing surgical strategy after evaluation by modern imaging technologies
Felix Kur, Andres Beiras-Fernandez, Martin Oberhoffer, Konstantin Nikolaou, et al.
Therapeutics and Clinical Risk Management 2009, 5:409-412
21 May 2009
Review
Luteal phase support in assisted reproductive technology treatment: focus on Endometrin® (progesterone) vaginal insert
Jerome H Check
Therapeutics and Clinical Risk Management 2009, 5:403-407
26 May 2009
Review
Recombinant factor VIII in the management of hemophilia A: current use and future promise
Jerry S Powell
Therapeutics and Clinical Risk Management 2009, 5:391-402
19 May 2009
Review
Managing Behçet’s disease: An update on current and emerging treatment options
P LA van Daele, J H Kappen, P M van Hagen, J AM van Laar
Therapeutics and Clinical Risk Management 2009, 5:385-390
13 May 2009
Review
Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting
Christina Ruhlmann, Jørn Herrstedt
Therapeutics and Clinical Risk Management 2009, 5:375-384
11 May 2009
Original Research
Fatty liver in children
Mandana Rafeey, Fakhrossadat Mortazavi, Nafiseh Mogaddasi, Ghergherehchi Robabeh, et al.
Therapeutics and Clinical Risk Management 2009, 5:371-374
08 May 2009
Review
Once-daily medications for the pharmacological management of ADHD in adults
Oleg v Tcheremissine, Lori M Lieving
Therapeutics and Clinical Risk Management 2009, 5:367-369
11 May 2009
Review
Anthracycline extravasation injuries: management with dexrazoxane
Karin Jordan, Timo Behlendorf, Franziska Mueller, Hans-Joachim Schmoll
Therapeutics and Clinical Risk Management 2009, 5:361-366
08 May 2009
Review
Current trends in the treatment of polycystic ovary syndrome with desire for children
Margalida E Sastre, Maria O Prat, Miguel Angel Checa, Ramon C Carreras
Therapeutics and Clinical Risk Management 2009, 5:353-360
08 May 2009
Review
Mycophenolic acid formulations in adult renal transplantation – update on efficacy and tolerability
Déla Golshayan, M Pascual, Bruno Vogt
Therapeutics and Clinical Risk Management 2009, 5:341-351
30 April 2009
Expert Opinion
Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
Christine Katlama, Robert Murphy
Therapeutics and Clinical Risk Management 2009, 5:331-340
30 April 2009
Original Research
Associations of anemia persistency with medical expenditures in Medicare ESRD patients on dialysis
Jiannong Liu, Haifeng Guo, David Gilbertson, Robert Foley, et al.
Therapeutics and Clinical Risk Management 2009, 5:319-330
22 April 2009
Review
Antimalarials and the fight against malaria in Brazil
Luiz MA Carmargo, Saulo de Oliveira, Sergio Basano, Célia RS Garcia
Therapeutics and Clinical Risk Management 2009, 5:311-317
22 April 2009
Review
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Silvia Migliaccio, Marina Brama, Nazzarena Malavolta
Therapeutics and Clinical Risk Management 2009, 5:305-310
17 April 2009
Case report
Cecal perforation with an ascending colon cancer caused by upper gastrointestinal endoscopy
Hiroyuki Miyatani, Yukio Yoshida, Hirokazu Kiyozaki
Therapeutics and Clinical Risk Management 2009, 5:301-303
03 April 2009
Review
Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
Sharath Gangadhara, Gianfilippo Bertelli
Therapeutics and Clinical Risk Management 2009, 5:291-300
02 April 2009
Review
Dasatinib in chronic myeloid leukemia: a review
Dolly G Aguilera, Apostolia M Tsimberidou
Therapeutics and Clinical Risk Management 2009, 5:281-289
27 March 2009
Review
Onset of action and seizure control in Lennox-Gaustaut syndrome: focus on rufinamide
Russell P Saneto, Gail D Anderson
Therapeutics and Clinical Risk Management 2009, 5:271-280
26 March 2009
Review
Recombinant human epoetin beta in the treatment of chemotherapy-related anemia
Iain RJ Macpherson, Colin R Lindsay, Nicholas S Reed
Therapeutics and Clinical Risk Management 2009, 5:261-270
16 March 2009
Review
Animal-derived surfactants for the treatment and prevention of neonatal respiratory distress syndrome: summary of clinical trials
J Wells Logan, Fernando R Moya
Therapeutics and Clinical Risk Management 2009, 5:251-260
12 March 2009
Short Report
Incidence and causes of neonatal hyperbilirubinemia in a center of Catania
Marco Sciuto, Gaetano Bertino, Mariangela Zocco, Ignazio Vecchio, et al.
Therapeutics and Clinical Risk Management 2009, 5:247-250
12 March 2009
Short Report
Challenging issues in molecular-targeted therapy
Zoheir Ezziane
Therapeutics and Clinical Risk Management 2009, 5:239-245
03 March 2009
Review
Role of oxaliplatin in the treatment of colorectal cancer
Pasquale Comella, Rossana Casaretti, Claudia Sandomenico, Antonio Avallone, Luca Franco
Therapeutics and Clinical Risk Management 2009, 5:229-238
04 March 2009
Original Research
Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations
Alberto Borgioli, Christian Viviani, Marco Duvina, Leila Brancato, Giuseppe Spinelli, et al
Therapeutics and Clinical Risk Management 2009, 5:217-227
27 February 2009
Original Research
Regimen complexity and medication nonadherence in elderly patients
Andrea Corsonello, Claudio Pedone, Fabrizia Lattanzio, Maria Lucchetti, Sabrina Garasto, et al.
Therapeutics and Clinical Risk Management 2009, 5:209-216
26 February 2009
Review
Fludarabine in the treatment of chronic lymphocytic leukemia: a review
Francesca Ricci, Alessandra Tedeschi, Enrica Morra, Marco Montillo
Therapeutics and Clinical Risk Management 2009, 5:187-207
04 March 2009
Review
Tenofovir and its potential in the treatment of hepatitis B virus
Laura Reynaud, Maria Aurora Carleo, Maria Talamo, Guglielmo Borgia
Therapeutics and Clinical Risk Management 2009, 5:177-185
02 February 2009
Review
Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
Roland D Chapurlat
Therapeutics and Clinical Risk Management 2009, 5:169-175
29 January 2009
Review
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin
Maurie Markman
Therapeutics and Clinical Risk Management 2009, 5:161-168
02 February 2009
Review
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma
Jatin J Shah, Robert Z Orlowski, Sheeba K Thomas
Therapeutics and Clinical Risk Management 2009, 5:151-159
22 January 2009
Review
Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection
Pranav Dalal, Monica Grafals, Darshika Chhabra, Lorenzo Gallon
Therapeutics and Clinical Risk Management 2009, 5:139-149
13 January 2009
Original Research
Nd: YAG capsulotomy for posterior capsule opacification after combined clear corneal phacoemulsification and vitrectomy
Ilias Georgalas, Petros Petrou, George Kalantzis, Dimitrios Papaconstantinou, Chrysanthi Koutsandrea, Ioannis Ladas
Therapeutics and Clinical Risk Management 2009, 5:133-137
11 January 2009
Review
Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses
Hideki Hasegawa, Takeshi Ichinohe, Akira Ainai, Shin-ichi Tamura, Takeshi Kurata
Therapeutics and Clinical Risk Management 2009, 5:125-132
09 March 2009
Original Research
A controlled, randomized nonblinded clinical trial to assess the efficacy of amphotericin B deoxycholate as compared to pentamidine for the treatment of antimony unresponsive visceral leishmaniasis cases in Bihar, India
Vidya Nand Rabi Das, Niyamat Ali Siddiqui, Krishna Pandey, Vijay Pratap Singh, Roshan K Topno, et al
Therapeutics and Clinical Risk Management 2009, 5:117-124
16 December 2008
Review
Role of atazanavir in the treatment of HIV infection
Pablo Rivas, Judit Morello, Carolina Garrido, Sonia Rodríguez-Nóvoa, Vincent Soriano
Therapeutics and Clinical Risk Management 2009, 5:99-116
17 December 2008
Review
A review of the use of exemestane in early breast cancer
Andrew Robinson
Therapeutics and Clinical Risk Management 2009, 5:91-98
11 December 2008
Review
Angioid streaks, clinical course, complications, and current therapeutic management
Ilias Georgalas, Dimitris Papaconstantinou, Chrysanthi Koutsandrea, George Kalantzis, Dimitris Karagiannis, et al
Therapeutics and Clinical Risk Management 2009, 5:81-89
09 December 2008
Review
A new extended release formulation (OROS®) of hydromorphone in the management of pain
Sharon M Weinstein
Therapeutics and Clinical Risk Management 2009, 5:75-80
09 December 2008
Review
Treatment and chemoprevention of NSAID-associated gastrointestinal complications
Edward J Frech, Mae F Go
Therapeutics and Clinical Risk Management 2009, 5:65-73
09 December 2008
Review
Progesterone for the prevention of preterm birth: indications, when to initiate, efficacy and safety
Helen Y How, Baha M Sibai
Therapeutics and Clinical Risk Management 2009, 5:55-64
09 December 2008
Case report
Life-threatening hemorrhage following subcutaneous heparin therapy
Jana Hudcova, Daniel Talmor
Therapeutics and Clinical Risk Management 2009, 5:51-54
02 December 2008
Review
Topical retapamulin in the management of infected traumatic skin lesions
Ribhi Shawar, Nicole Scangarella-Oman, MaryBeth Dalessandro, John Breton, Monique Twynholm, et al
Therapeutics and Clinical Risk Management 2009, 5:41-49
04 December 2008
Original Research
Voiding cystourethrogram in the diagnosis of vesicoureteric reflux in children with antenatally diagnosed hydronephrosis
R B Nerli, S S Amarkhed, I R Ravish
Therapeutics and Clinical Risk Management 2009, 5:35-39
02 December 2008
Review
Management of postoperative nausea and vomiting: focus on palonosetron
Neil A Muchatuta, Michael J Paech
Therapeutics and Clinical Risk Management 2009, 5:21-34
30 November 2008
Case report
Severe hypotony and filtering bleb leak after intravitreal injection of ranibizumab
Ilias Georgalas, Dimitris Papaconstantinou, Ioannis Tservakis, Chrysanthi Koutsandrea, Ioannis Ladas
Therapeutics and Clinical Risk Management 2009, 5:17-19
27 November 2008
Original Research
Regular use of traditional analgesics predicts major coronary events: A cohort study
Mikko Haara, Markku Heliövaara, Jari PA Arokoski, Paul Knekt, Pirjo Manninen, et al
Therapeutics and Clinical Risk Management 2009, 5:9-15
02 December 2008
Review
Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007
Jennifer D Peterson, Lawrence S Chan
Therapeutics and Clinical Risk Management 2009, 5:1-7
25 November 2008
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
